HISTONE THERAPEUTICS

Seattle, WA · Biotech · Private

Epigenetically modified natural killer cells for cancer immunotherapy

histonetx.com →
Grants
$273K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I:Epigenetic Remodeling of Natural Killer (NK) Cells for Blood Cancer Therapies$273,388
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3199Jortan Pharmaceuticals Inc.——
3200TheraCea Pharma LC——
3201SAHANE BIOTECH INC——
3202HISTONE THERAPEUTICS——
3203NAJIT TECHNOLOGIES, INC.——
3204OM THERAPEUTICS INC.——
3205Anaveon——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Compositions For Gene Activation Comprising P300 Dna Binding Domains And Associated Methodsapplication
  • Compositions For Gene Activation Comprising P300 Dna Binding Domains And Associated Methodsapplication
  • Compositions For Gene Activation Comprising P300 Dna Binding Domains And Associated Methodsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.